Six months after subcutaneous implantable cardioverter defibrillator (S‐ICD) implantation a 26‐year‐old Brugada patient presented because of a beeping tone emitted by his device. Chest X‐ray displayed two functionless transvenous shock leads and the S‐ICD system with a lead fracture. During lead revision procedure, extensive preparation of the lead from unexpectedly firm surrounding fibrous tissue encapsulating the lead was necessary before it could be removed, and a new shock lead could be implanted. This is the first report of an S‐ICD lead exchange due to very early lead fracture and unexpectedly severe fibrous tissue hampering surgical lead extraction.
Objectives To assess feasibility and safety of second‐generation left atrial appendage closure (LAAC) Ultraseal device in patients with nonvalvular atrial fibrillation (NVAF). Background LAAC with first‐generation Ultraseal device (Cardia, Eagan, Minnesota) has been shown to be a feasible therapeutic option in patients with NVAF. However, there is a paucity of data regarding the novel second‐generation Ultraseal device. Methods All patients with NVAF undergoing second‐generation Ultraseal device implantation between February 2018 and September 2020 were included in a multicenter international registry. Periprocedural and post‐discharge events were collected through 6‐month follow‐up. Co‐primary efficacy endpoints were device success and technical success while primary safety endpoint was in‐hospital major adverse event (MAE) occurrence. Results A total of 52 patients were included: mean age 75 ± 8, 30.8% women, mean HAS‐BLED 3 ± 1. The device was successfully implanted in all patients. Technical success was achieved in 50 patients (96.1%). In‐hospital MAEs occurred in three patients (5.8%). The incidence of 6‐month all‐cause death and major bleeding was 11.6% and 2.1%, respectively. No strokes, transient ischemic attacks, systemic embolisms, or device embolization were reported after discharge. Conclusions Second‐generation Ultraseal device implantation was associated with high success rates and a low incidence of peri‐procedural complications. Larger studies with longer follow‐up are warranted to further evaluate the safety and the efficacy of this device, especially at long‐term follow‐up.
St. Jude Medical produces the implantable loop recorder (ILR) Confirm AF DM2102 which offers subcutaneous electrodes on both sides of the device, a specific sensing algorithm and extensive storage capacity for up to 147 episodes. The reliability of detection of atrial fibrillation (AF) has been evaluated in the DETECT-AF study. The device is MR-conditional and allows patients an interrogation at home. The data are transferred to the follow-up centre via telephone by the patient activator, although this process is currently rather complex and slow. Therefore, remote monitoring of the Confirm AF DM2102 is rarely an option for elderly patients. St. Jude medical announced the introduction of a new, substantially smaller ILR using more modern technology by the end of 2016.
Drug-eluting stents (DES) are the gold standard for percutaneous coronary interventions (PCI); however, technical and anatomical challenges need to be addressed to ensure optimal apposition and prevent late adverse events. Complex vessel anatomies, including ectatic or aneurysmatic vessels, or significant differences in diameter in left main stenosis of the coronary artery, are clinical indications in which current PCI techniques attempt to shape conventional DES to follow vessel anatomy, thus modifying the original stent scaffold and its properties. However, due to their design, balloon-expandable cobalt–chromium and cobalt–nickel DES have limitations regarding their expansion capacity, which can result in undersizing and malapposition. New stent scaffolds have recently been introduced into clinical practice to address these challenging anatomies, including a drug-eluting nitinol stent platform. The nature of the nitinol device allows conformability to the native vessel, covering complex anatomies without manual adaptation. In this article, the authors present the rationale and current data on self-apposing nitinol DES in left main stenosis, and suggest that the device may be safely and effectively used with comparable rates of adverse cardiovascular events, as seen with second-generation balloon-expandable DES.
Mitral valve dysfunction affects around 2% of the population and its incidence is still increasing, making it the second most common valvular heart disease, after aortic stenosis. Depending on the etiology of the disease, it can be classified into primary or secondary mitral regurgitation. The first line of treatment is optimal medical therapy. If ineffective, mitral valve intervention can be considered. For patients disqualified from surgical treatment, transcatheter edge-to-edge repair with the use of MitraClip may be considered. Over 100,000 MitraClip procedures have been performed which makes this the most established transcatheter technique for the treatment of severe mitral regurgitation. The aim of this review is to discuss the technical details of the MitraClip procedure, clinical evidence regarding the efficacy of MitraClip, complications related to the clip implantation alongside with acute complications based on the currently available evidence and clinical experience.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.